脓毒性休克患者持续输注去甲肾上腺素前推注去氧肾上腺素的效果
这项回顾性多中心队列研究纳入1317例启动去甲肾上腺素的成人脓毒性休克患者,181例接受初始去氧肾上腺素推注,经倾向评分1:2匹配后141例推注患者与282例未推注患者比较。主要终点为去甲肾上腺素启动后3小时和12小时内达到血流动力学稳定(MAP≥65 mmHg持续至少6小时且无需增加持续输注血管活性药物剂量)。推注组3小时稳定率更高(28.4% vs 18.8%;风险差10%;95%CI 0.9%-18%),校正OR 1.8(95%CI 1.09-2.97),但12小时无显著差异(校正OR 1.42;95%CI 0.93-2.16)。推注与更高的ICU死亡率独立相关(校正OR 1.88;95%CI 1.1-3.21)。
要点
- 在脓毒性休克启动去甲肾上腺素前推注去氧肾上腺素,3小时血流动力学稳定率28.4% vs 18.8%,风险差10%(95%CI 0.9%-18%)。
- 推注去氧肾上腺素与3小时血流动力学稳定独立相关(校正OR 1.8;95%CI 1.09-2.97),但与12小时稳定无关(校正OR 1.42;95%CI 0.93-2.16)。
- 推注去氧肾上腺素与更高的ICU死亡率独立相关(校正OR 1.88;95%CI 1.1-3.21),临床决策需权衡早期获益与潜在风险。
- 血流动力学稳定定义为MAP≥65 mmHg持续至少6小时且无需增加持续输注血管活性药物剂量。
- 该研究为回顾性多中心队列,存在残余混杂可能,结果需前瞻性验证。
适用人群与场景
- 成人脓毒性休克患者,已启动去甲肾上腺素持续输注。
- 研究排除人群原文未提及。
- 场景为ICU(原文提及ICU死亡率),急诊/院前场景原文未提及。
诊断标准与关键阈值
- 血流动力学稳定定义为维持MAP≥65 mmHg至少6小时,且无需增加持续输注血管活性药物剂量。
- 评估时间点为去甲肾上腺素启动后3小时和12小时。
处置流程与药物剂量
- 原文未提及去氧肾上腺素推注的具体剂量、单位、给药途径、频次或疗程。
- 原文未提及去甲肾上腺素的具体剂量、单位、给药途径、频次或目标值。
- 原文未提及推注去氧肾上腺素后达到MAP目标的具体调整流程。
红旗征与不能漏的情况
- 推注去氧肾上腺素与更高的ICU死亡率独立相关(校正OR 1.88;95%CI 1.1-3.21),需警惕。
- 早期血流动力学稳定(3小时)获益未能持续至12小时(校正OR 1.42;95%CI 0.93-2.16),不能因早期稳定而放松监测。
研究设计与关键结果
- 研究类型:回顾性、多中心队列研究;纳入1317例成人脓毒性休克启动去甲肾上腺素患者,其中181例接受初始去氧肾上腺素推注。
- 倾向评分1:2匹配后,141例推注患者与282例未推注患者比较。
- 主要终点:3小时血流动力学稳定率推注组28.4% vs 未推注组18.8%;风险差10%(95%CI 0.9%-18%)。
- 推注去氧肾上腺素与3小时血流动力学稳定独立相关(校正OR 1.8;95%CI 1.09-2.97)。
- 推注去氧肾上腺素与12小时血流动力学稳定无独立相关(校正OR 1.42;95%CI 0.93-2.16)。
- 推注去氧肾上腺素与更高的ICU死亡率独立相关(校正OR 1.88;95%CI 1.1-3.21)。
- 关键次要终点和不良事件原文未提及。
证据类型、等级与局限
- 证据类型:回顾性、多中心队列研究。
- 证据等级或推荐强度原文未提及。
- 局限:回顾性设计,可能存在残余混杂;原文未提及单中心、开放标签、样本量等局限。
对床旁实践的改变
- 在脓毒性休克患者启动去甲肾上腺素前,推注去氧肾上腺素可能提高3小时血流动力学稳定率,但不应预期12小时持续稳定。
- 鉴于推注去氧肾上腺素与更高ICU死亡率独立相关,临床医生考虑该做法时应谨慎权衡早期获益与潜在风险。
- 适用与不适用人群、常见陷阱原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: IV pushes of phenylephrine may be used for patients with septic shock with the intent of rapidly achieving mean arterial pressure (MAP) goals. However, the clinical effectiveness and safety of this approach are unclear.
RESEARCH QUESTION: In patients with septic shock, is administration of a phenylephrine push before norepinephrine initiation associated with a higher incidence of hemodynamic stability?
METHODS: This retrospective, multicenter cohort study included adult patients with septic shock initiated on norepinephrine. Propensity scores for initial phenylephrine push receipt were generated, and patients receiving an initial phenylephrine push were propensity score-matched 1:2 to those not receiving an initial phenylephrine push. The primary outcome was achievement of hemodynamic stability (defined as maintaining MAP of ≥ 65 mm Hg for at least 6 h without an increase in continuous infusion vasoactive agent dosage) within 3 and 12 h of norepinephrine initiation.
RESULTS: Of 1,317 included patients, 181 received an initial phenylephrine push; 141 phenylephrine push patients were matched to 282 patients not receiving a phenylephrine push. More patients who received a phenylephrine push achieved hemodynamic stability at hour 3 than those who did not receive a phenylephrine push (28.4% vs 18.8%; risk difference, 10%; 95% CI, 0.9%-18%). Phenylephrine push receipt was associated independently with hemodynamic stability within 3 h (adjusted OR, 1.8; 95% CI, 1.09-2.97), but not at 12 h (adjusted OR, 1.42; 95% CI, 0.93-2.16). Phenylephrine push receipt was associated independently with higher ICU mortality (adjusted OR, 1.88; 95% CI, 1.1-3.21).
INTERPRETATION: Phenylephrine pushes were associated with a higher incidence of early, but not sustained, hemodynamic stability and were associated independently with higher ICU mortality. Caution is warranted when clinicians are considering the use of phenylephrine pushes in patients with septic shock.
参考来源
- Hawn JM, Bauer SR, Yerke J, et al. Effect of Phenylephrine Push Before Continuous Infusion Norepinephrine in Patients With Septic Shock. Chest. 2020. PMID: 33316239. doi:10.1016/j.chest.2020.11.051
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。